Camden Property Trust has agreed to pay $53 million to settle claims in a civil case related to the use of RealPage software, denying fault or liability. This settlement follows a broader class-action lawsuit alleging rent-fixing involving multiple landlords and RealPage's YieldStar software. The Department of Justice also settled with RealPage last November, which included platform changes and independent oversight.

This article provides a stock quote and related information for the MFS Active Core Plus Bond ETF (MFSB). It details its current trading price, volume, bid/ask, daily and 52-week ranges, dividend yield, and recent performance metrics. Additionally, it includes frequently asked questions about the ETF's trading status and exchange.

JPMorgan Chase & Co. has reduced its price target for Cheniere Energy (NYSE:LNG) from $338 to $325, while maintaining an "overweight" rating. This new target still suggests about a 25% upside for the stock. Despite JPMorgan's reduction, other major analysts have largely increased their price targets and ratings, contributing to a consensus "Moderate Buy" rating with an average target of $292.82.

FirstEnergy (NYSE: FE) is investing $24 million to rebuild nearly three miles of the Niles Central-Packard 138-kV transmission line in Trumbull County, Ohio, enhancing service reliability for over 16,000 Ohio Edison customers. The project involves replacing wooden poles with 22 steel structures and installing thicker wire, aimed at reducing outages and improving restoration times. This upgrade is part of FirstEnergy's larger $36 billion Energize365 program for grid modernization between 2026 and 2030.

Bank of America has lowered its price target for Travelers Companies (NYSE:TRV) from $259 to $257, maintaining an "underperform" rating and implying a 14.18% downside. Despite the cut, Travelers exceeded quarterly earnings and revenue expectations and authorized a $5 billion share buyback. However, insider selling has been noted, and analyst opinions on the stock remain mixed with a consensus "Hold" rating across the board.

Direxion Daily MSFT Bull 2X Shares (NASDAQ:MSFU) experienced an unusually high volume of call options trading on Tuesday, with 4,014 call options purchased, a 106% increase from the typical volume. The shares also saw a significant jump of 4.8% to $25.88 on high trading volume. Several institutional investors adjusted their positions, and the fund recently declared a quarterly dividend.

Kiora Pharmaceuticals announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine, confirming the drug's safety and feasibility in late-stage retinitis pigmentosa patients. KIO-301, a molecular photoswitch, aims to restore light responsiveness regardless of genetic mutation. Building on these positive findings, the company has initiated a randomized, controlled Phase 2 clinical trial (ABACUS-2) to further evaluate higher doses and functional visual improvements.

This article examines whether Alphabet Inc.'s robust AI integration can drive new upside for its Class C stock, weighing this growth potential against regulatory pressures. It delves into Alphabet's core business model, competitive position in advertising and cloud computing, and the significance of AI as a key growth driver, advising investors on what to monitor next.

The U.S. Department of Defense has awarded Lockheed Martin a contract valued at up to $1.9 billion. This contract is for continuing to provide training systems and support for the C-130J military transport aircraft. The agreement's structure was detailed in a company release.

Thermo Fisher Scientific has partnered with Precision Health Research, Singapore (PRECISE) on the PRECISE-SG100K study, a population-scale biobank initiative. This collaboration aims to leverage multi-omic platforms and AI-driven analytics, particularly proteomics, to identify disease patterns, improve patient stratification, and advance personalized healthcare. The study will utilize Thermo Fisher's Olink and Orbitrap Astral systems, alongside Seer Proteograph Product Suite, generating insights into disease biology within Singapore's diverse population.